1-5 of 5
Zi Chen, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)

Ming Lu, PhD, Chenhui Deng, PhD, Yifeng Xiong, PhD, Hengbang Wang, Ping Xu, PhD, Lichuang Men, Tanhong Xie, Qian Jiang, MD, Zi Chen, MD, Qian Niu, MD, Ping Liu, PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-141268
Published: 2020
Journal Articles

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, MD, Xiaojun Huang, MD, Zi Chen, MD, Qian Niu, MD, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, MD, Weiming Li, PhD, Xiaoli Liu, Na Xu, Yongping Song, MD, Yanli Zhang, Li Meng, MDPhD, Zhenya Hong, MDPhD, Bingcheng Liu, Shan Zeng, Lichuang Men, Yan Li, MD, Suning Chen, Mengxing Xue, PhD, Huanling Zhu, MD, He Li, Xin Du, Jin Lou, MD, Xiaohan Zhang, Yang Liang, MD, Yujun Dai, MD PhD, Ming Lu, PhD, Hengbang Wang, Jiao JI, PhD MD, Changai Yue, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-142142
Published: 2020
Journal Articles

An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3 rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia

Qian Jiang, MD, Xiaojun Huang, MD, Zi Chen, MD, Qian Niu, Lichuang Men, Hengbang Wang, PhD, Jiao JI, PhD MD, Bo Huang, Dayu Shi, Ting Zhao, Yue Hou, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 493.
https://doi.org/10.1182/blood-2019-124295
Published: 2019
Journal Articles

Safety and Efficacy of HQP1351, a 3 rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor—Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study

Qian Jiang, MD, Xiao Jun Huang, Zi Chen, MD, Lichuang Men, Wei Liu, Xuemei Sun, Jiao JI, PhD MD, Hengbang Wang, Yue Hou, Po Hu, Lei Zou, Hua Yan, Yingjie Huang, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 791.
https://doi.org/10.1182/blood-2018-99-119142
Published: 2018
Journal Articles

Impact of I(17q) in Myeloproliferative Neoplasms

Zimu Gong, MD, Zi Chen, MD, Srdan Verstovsek, MD PhD, Jorge E. Cortes, MD, Arash Ronaghy, MD, Wei Wang, MD PhD, Carlos E. Bueso-Ramos, MD PhD, L. Jeffrey Medeiros, MD, Shimin Hu, PhD MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2911.
https://doi.org/10.1182/blood.V130.Suppl_1.2911.2911
Published: 2017